The Significant Influence of the Neuroendocrine Component on the Survival of Patients with Gastric Carcinoma Characterized by Coexisting Exocrine and Neuroendocrine Components

Overview

Journal J Oncol

Specialty Oncology

Date 2019 Apr 18

PMID 30992704

Citations 4

Authors

Hu Ren

Su-Sheng Shi

Nian-Chang Wang

Xing Wang

Ying-Tai Chen

Dong-Bing Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Gastric adenocarcinoma patients with a neuroendocrine (NE) component are frequently observed in routine practice. Several previous studies have investigated the influence of a NE component on the survival of these patients; however, the results were inconsistent.

Methods: We retrospectively investigated a consecutive series of 95 gastric adenocarcinoma patients with a NE component and 190 gastric adenocarcinoma patients without a NE component. We adopted 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% as the cut-off proportions of the NE component, respectively, and analyzed the patients' overall survival according to the proportion of the NE component.

Results: The 1-, 3-, and 5-year actual survival rates of the patients with a NE component were 90.1%, 72.3%, and 67.2%, respectively, and for those without a NE component 94.2%, 79.3%, and 75.7%, respectively. The multivariate analysis showed that the patients with NE components >70% (HR: 2.156; 95% CI: 1.011, 4.597; ) and >90% (HR: 2.476; 95% CI: 1.088, 5.634; ) had significantly worse survival than those without a NE component. Only the diameter of tumors (>4.64 cm) (HR: 2.585; 95% CI: 1.112, 6.006; ) and pN3 (HR: 2.953; 95% CI: 1.051, 8.293; ) were independently associated with worse overall survival for gastric adenocarcinoma patients with a NE component (all ).

Conclusion: Gastric adenocarcinoma patients with a NE component >70% and >90% have significantly worse survival than those without a NE component. Only the diameter of tumors and the number of metastatic lymph nodes are independent prognostic factors for gastric adenocarcinoma patients with a NE component.

Citing Articles

Clinicopathological characteristics of gastric neuroendocrine neoplasms: A comprehensive analysis.

Zi M, Ma Y, Chen J, Pang C, Li X, Yuan L Cancer Med. 2024; 13(4):e7011.

PMID: 38457192 PMC: 10922030. DOI: 10.1002/cam4.7011.

Equivalent Survival between Gastric Large-Cell Neuroendocrine Carcinoma and Gastric Small-Cell Neuroendocrine Carcinoma.

Li Z, Ren H, Zhang X, Sun C, Fei H, Li Z J Clin Med. 2023; 12(18).

PMID: 37762979 PMC: 10531653. DOI: 10.3390/jcm12186039.

Better Prognosis of Gastric Neuroendocrine Carcinoma Than Gastric Adenocarcinoma among Whites in the United States: A Propensity Score Matching Analysis Based on SEER.

Li Z, Ren H, Zhao L, Zhang X, Wang T, Sun C Curr Oncol. 2022; 29(7):4879-4892.

PMID: 35877247 PMC: 9323980. DOI: 10.3390/curroncol29070387.

Serum lipid levels correlate to the progression of gastric cancer with neuroendocrine immunophenotypes: A multicenter retrospective study.

Zou Y, Wu L, Yang Y, Ding Z, Huang J, Li P Transl Oncol. 2020; 14(1):100925.

PMID: 33137542 PMC: 7644677. DOI: 10.1016/j.tranon.2020.100925.

References

Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S . ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology. 1999; 116(3):532-42. DOI: 10.1016/s0016-5085(99)70174-5. View

Fukui H, Takada M, Chiba T, Kashiwagi R, Sakane M, TABATA F . Concurrent occurrence of gastric adenocarcinoma and duodenal neuroendocrine cell carcinoma: a composite tumour or collision tumours ?. Gut. 2001; 48(6):853-6. PMC: 1728320. DOI: 10.1136/gut.48.6.853. View

Japanese Gastric Cancer Association . Japanese Classification of Gastric Carcinoma - 2nd English Edition -. Gastric Cancer. 2002; 1(1):10-24. DOI: 10.1007/s101209800016. View

Furlan D, Cerutti R, Genasetti A, Pelosi G, Uccella S, La Rosa S . Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut. Lab Invest. 2003; 83(7):963-71. DOI: 10.1097/01.lab.0000079006.91414.be. View

Nishikura K, Watanabe H, Iwafuchi M, Fujiwara T, Kojima K, Ajioka Y . Carcinogenesis of gastric endocrine cell carcinoma: analysis of histopathology and p53 gene alteration. Gastric Cancer. 2004; 6(4):203-9. DOI: 10.1007/s10120-003-0249-0. View

Eren F, Celikel C, Gulluoglu B . Neuroendocrine differentiation in gastric adenocarcinomas; correlation with tumor stage and expression of VEGF and p53. Pathol Oncol Res. 2004; 10(1):47-51. DOI: 10.1007/BF02893409. View

Bakkelund K, Fossmark R, Nordrum I, Waldum H . Signet ring cells in gastric carcinomas are derived from neuroendocrine cells. J Histochem Cytochem. 2005; 54(6):615-21. DOI: 10.1369/jhc.5A6806.2005. View

Jiang S, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I . Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol. 2006; 30(8):945-53. DOI: 10.1097/00000478-200608000-00003. View

Boo Y, Park S, Kim J, Mok Y, Kim S, Kim C . Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers. J Surg Oncol. 2006; 95(2):110-7. DOI: 10.1002/jso.20616. View

10.

Sasako M, Saka M, Fukagawa T, Katai H, Sano T . Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg. 2007; 24(2):101-7. DOI: 10.1159/000101896. View

11.

Pape U, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M . Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008; 15(4):1083-97. DOI: 10.1677/ERC-08-0017. View

12.

Washington K . 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010; 17(12):3077-9. DOI: 10.1245/s10434-010-1362-z. View

13.

Bartley A, Rashid A, Fournier K, Abraham S . Neuroendocrine and mucinous differentiation in signet ring cell carcinoma of the stomach: evidence for a common cell of origin in composite tumors. Hum Pathol. 2011; 42(10):1420-9. DOI: 10.1016/j.humpath.2010.12.008. View

14.

Terada T, Maruo H . Simultaneous large cell neuroendocrine carcinoma and adenocarcinoma of the stomach. World J Gastroenterol. 2011; 17(43):4831-4. PMC: 3229634. DOI: 10.3748/wjg.v17.i43.4831. View

15.

Kubota T, Ohyama S, Hiki N, Nunobe S, Yamamoto N, Yamaguchi T . Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute. Gastric Cancer. 2012; 15(3):323-30. DOI: 10.1007/s10120-011-0122-5. View

16.

Huang J, Zhou Y, Zhao X, Zhang H, Yuan X, Wang J . Primary small cell carcinoma of the stomach: an experience of two decades (1990-2011) in a Chinese cancer institute. J Surg Oncol. 2012; 106(8):994-8. DOI: 10.1002/jso.23186. View

17.

Kitagawa M, Ichikawa D, Komatsu S, Okamoto K, Shiozaki A, Fujiwara H . Evaluation of lymph node metastasis in patients with gastric cancer: a comparison of the directionality of lymph node metastasis and the total number of metastatic lymph nodes. Surg Today. 2012; 43(2):130-5. DOI: 10.1007/s00595-012-0454-8. View

18.

Kapoor N, Shamonki J, Sim M, Chung C, Giuliano A . Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer. Ann Surg Oncol. 2013; 20(8):2576-81. DOI: 10.1245/s10434-013-2924-7. View

19.

Young H, Carr N, Green B, Tilley C, Bhargava V, Pearce N . Accuracy of visual assessments of proliferation indices in gastroenteropancreatic neuroendocrine tumours. J Clin Pathol. 2013; 66(8):700-4. DOI: 10.1136/jclinpath-2012-201217. View

20.

Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H . Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013; 37(7):949-59. DOI: 10.1097/PAS.0b013e31828ff59d. View